DailyIQ
|
Sector:HealthcareAll sectors
Last updated 3 minutes ago

LH·Labcorp Holdings Inc.

$.
-. (-.%)
After Hours
High
$280.85
Open
$278.00
Market Cap
22.70B
52W High
$293.72
Low
$276.00
P. Close
$276.78
P/E
24.11
52W Low
$241.81
Fwd P/E
14.24
DailyIQ Est.
$318.26
Technical Score (1D)
82
BUY
News Sentiment
49
MIXED
Labcorp declared a quarterly cash dividend of $0.72 per share, payable September 11, 2026 with a record date of August 28, 2026, underscoring management’s confidence in its cash flow and a modest yield for investors. The payout aligns with the company’s historical dividend trajectory, suggesting an intent to maintain shareholder returns while preserving earnings growth. Traders should monitor the ex‑dividend date for potential short‑term price adjustments and assess whether the dividend will influence valuation multiples in the coming days. On July 30, 2026, Labcorp will report its Q2 2026 earnings, with a webcast scheduled at 9:00 a.m. ET, providing a key opportunity to gauge revenue growth, margin trends, and the impact of recent acquisitions. The earnings release could confirm or revise expectations for low‑double‑digit earnings growth, affecting the stock’s momentum over the next trading week. Earlier this year, Labcorp secured FDA approval and Medicare coverage for its ColoSense at‑home colorectal cancer test, expanding its colorectal screening portfolio and potentially boosting revenue streams. This development may drive incremental demand among Medicare beneficiaries, and the company’s ability to capture market share will be a critical factor to watch as adoption rates unfold. The company’s Q1 results already showed revenue growth and margin expansion relative to peers, reinforcing its competitive positioning in the diagnostics sector. Investors should keep an eye on any guidance regarding cost management, especially in light of rising cost pressures and macro headwinds such as inflation and currency fluctuations. Finally, monitoring the timing of the dividend payout and the Q2 earnings webcast will be essential to anticipate any short‑term valuation shifts and to gauge how the new ColoSense product may translate into revenue growth.
Earnings Summary
Labcorp Holdings Inc. (LH) is a leading provider of laboratory diagnostics and biopharma services, operating through Diagnostics Laboratories and Biopharma Laboratory Services segments that serve healthcare providers, pharmaceutical companies, and managed care organizations. The company’s extensive network of approximately 2,000 patient‑service centers and a portfolio of 5,000 clinical tests, ranging from routine panels to high‑complexity oncology and genomic assays, anchors it in the diagnostics and research sector. In Q4 2024, LH reported EPS of $3.45 versus an estimate of $3.39, and revenue of $3.329 billion, a modest 0.2% increase over the prior year’s $3.292 billion. Q1 2025 delivered EPS of $3.84 against an estimate of $3.73, and revenue of $3.345 billion, a 0.4% YoY rise. Q2 2025 saw EPS of $4.35 versus $4.18, and revenue of $3.527 billion, a 5.5% increase. Q3 2025 posted EPS of $4.18 versus $4.14, and revenue of $3.563 billion, a 1.2% rise. Q4 2025 produced EPS of $4.07 versus $3.94, and revenue of $3.516 billion, a 0.8% increase. Q1 2026 reported EPS of $4.25 versus $4.22, and revenue of $3.538 billion, a 0.6% rise. Across the last six quarters, LH has consistently beaten EPS estimates and maintained steady revenue growth, though the company’s revenue has declined 1.6% annually over the past five years, indicating a slowing organic growth trajectory. Recent news highlights the nationwide rollout of ColoSense, the first FDA‑approved RNA‑based at‑home colorectal cancer screening test now covered for Medicare, and the upcoming Q2 2026 earnings webcast, both of which could strengthen the company’s at‑home testing portfolio and provide a new revenue stream. Investors should watch the Q2 2026 earnings release for guidance nuances, Medicare policy updates that could affect ColoSense reimbursement, and any regulatory developments on genomic testing that may influence pricing dynamics and payer negotiations.

EPS

EstBeatMiss
$3.58$3.92$4.25$4.59$4.93Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$4.77 - -
Q1'26$4.22$4.25+0.8%
Q4'25$3.94$4.07+3.2%
Q3'25$4.14$4.18+1.0%
Q2'25$4.18$4.35+4.1%
Q1'25$3.73$3.84+2.8%

Revenue

EstBeatMiss
$3.3B$3.4B$3.6B$3.7B$3.9BQ1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$3.8B - -
Q1'26$3.6B$3.5B-2.0%
Q4'25$3.6B$3.5B-1.2%
Q3'25 - $3.6B -
Q2'25 - $3.5B -
Q1'25 - $3.3B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

LH Stock Snapshot

LH is currently trading at $276.81, giving Labcorp Holdings Inc. a market cap of 22.70B and a P/E ratio of 24.1. Today's range spans $276.00–$280.85, with shares opening at $278.00 and moving up $0.03 (0.0%) from the prior close. DailyIQ's technical score sits at 82/100 (BUY) with a news sentiment reading of 49/100.

Over the past year LH has traded between $241.81 and $293.72 - the current price is +14.5% off the 52-week low and -5.8% from the high. 30 analysts cover the stock with a Buy consensus and a mean 12-month target of $311.00 (range $270.00–$340.00), implying upside of +12.4%.

LH is scoring 82/100 technically (BUY) and sits at $276.81 - in the middle of its 52-week range in its $241.81–$293.72 annual range. Sentiment at 49/100 is neutral. At 22.70B in Healthcare market cap The current P/E ratio stands at 24.1., this is the tier where earnings revision cycles have the most impact on price: upward revisions in a large-cap company with bullish momentum tend to attract analyst upgrades, which in turn attract new institutional mandates.

Earnings revision cycles in large-cap Healthcare names tend to compound: when technicals confirm a BUY thesis (82/100) and news sentiment (49/100, neutral) supports the narrative, analyst upgrades follow price rather than lead it. At $276.81 (in the middle of its 52-week range), LH's position within the $241.81–$293.72 annual range suggests there's room for multiple expansion before the stock encounters meaningful technical resistance.